223 related articles for article (PubMed ID: 1453204)
1. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.
Lashford LS; Lewis IJ; Fielding SL; Flower MA; Meller S; Kemshead JT; Ackery D
J Clin Oncol; 1992 Dec; 10(12):1889-96. PubMed ID: 1453204
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study.
Fielding SL; Flower MA; Ackery D; Kemshead JT; Lashford LS; Lewis I
Eur J Nucl Med; 1991; 18(5):308-16. PubMed ID: 1936038
[TBL] [Abstract][Full Text] [Related]
3. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
Buckley SE; Chittenden SJ; Saran FH; Meller ST; Flux GD
J Nucl Med; 2009 Sep; 50(9):1518-24. PubMed ID: 19713562
[TBL] [Abstract][Full Text] [Related]
4. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.
Flower MA; Fielding SL
Phys Med Biol; 1996 Oct; 41(10):1933-40. PubMed ID: 8912372
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
7. Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine.
Sisson JC; Shapiro B; Hutchinson RJ; Carey JE; Zasadny KR; Zempel SA; Normolle DP
Eur J Nucl Med; 1994 Jan; 21(1):46-52. PubMed ID: 8088285
[TBL] [Abstract][Full Text] [Related]
8. Iodine-125-MIBG to treat neuroblastoma: preliminary report.
Sisson JC; Hutchinson RJ; Shapiro B; Zasadny KR; Normolle D; Wieland DM; Wahl RL; Singer DA; Mallette SA; Mudgett EE
J Nucl Med; 1990 Sep; 31(9):1479-85. PubMed ID: 2395016
[TBL] [Abstract][Full Text] [Related]
9. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
[TBL] [Abstract][Full Text] [Related]
11. The treatment of resistant neuroblastoma with 131I-mIBG: alternative methods of dose prescription.
Fielding SL; Flower MA; Ackery DM; Kemshead J; Lashford LS; Lewis IJ
Radiother Oncol; 1992 Sep; 25(1):73-6. PubMed ID: 1410594
[TBL] [Abstract][Full Text] [Related]
12. Toxicity from treatment of neuroblastoma with 131I-meta-iodobenzylguanidine.
Sisson JC; Hutchinson RJ; Carey JE; Shapiro B; Johnson JW; Mallette SA; Wieland DM
Eur J Nucl Med; 1988; 14(7-8):337-40. PubMed ID: 3181182
[TBL] [Abstract][Full Text] [Related]
13. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
DuBois SG; Messina J; Maris JM; Huberty J; Glidden DV; Veatch J; Charron M; Hawkins R; Matthay KK
J Clin Oncol; 2004 Jun; 22(12):2452-60. PubMed ID: 15197208
[TBL] [Abstract][Full Text] [Related]
14. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
15. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
[TBL] [Abstract][Full Text] [Related]
16. [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects.
Klingebiel T; Treuner J; Ehninger G; Keller KD; Dopfer R; Feine U; Niethammer D
Cancer Chemother Pharmacol; 1989; 25(2):143-8. PubMed ID: 2598401
[TBL] [Abstract][Full Text] [Related]
17. Treatment of neuroblastoma with [125I]metaiodobenzylguanidine.
Sisson JC; Shapiro B; Hutchinson RJ; Zasadny KR; Mallette S; Mudgett EE; Wieland DM
J Nucl Biol Med (1991); 1991; 35(4):255-9. PubMed ID: 1823830
[TBL] [Abstract][Full Text] [Related]
18. 131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma.
Hutchinson RJ; Sisson JC; Shapiro B; Miser JS; Normole D; Shulkin BL; Francis IR; Zasadny K; Carey JE; Johnson JW
Am J Clin Oncol; 1992 Jun; 15(3):226-32. PubMed ID: 1590275
[TBL] [Abstract][Full Text] [Related]
19. Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives.
Beierwaltes WH
Med Pediatr Oncol; 1987; 15(4):188-91. PubMed ID: 3657705
[TBL] [Abstract][Full Text] [Related]
20. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]